Arcus Biosciences Announces the Promotion of Jennifer Jarrett to Chief Operating Officer
“Since joining Arcus, Jennifer has successfully built out our finance, investor relations and corporate communications functions and played a central role in our fundraising and business development activities,” said Terry Rosen, Ph.D., Chief Executive Officer at Arcus. “Jennifer’s promotion to Chief Operating Officer reflects a recognition of her outstanding leadership and the impact that she has had across the breadth of Arcus’s operations to date and our company’s increasing focus on portfolio prioritization and early commercial planning. We will benefit greatly from Jennifer’s extensive knowledge of the commercial landscape and the vision that she brings to the careful consideration of the numerous opportunities and challenges associated with the next-generation immuno-oncology agents we are advancing into and through clinical development.”
Ms. Jarrett joined Arcus in 2017 and has over 20 years of experience in biotechnology. Prior to joining Arcus, Ms. Jarrett was the Chief Financial Officer of Medivation, through its acquisition by Pfizer in September 2016; there, she was responsible for finance and accounting, investor relations, business development and information technology. Prior to Medivation, Ms. Jarrett spent 18 years in investment banking, most recently as a Managing Director in Citigroup’s Health Care Investment Banking Group, where she built and led their west coast biotechnology investment banking practice. Ms. Jarrett also serves on the Board of Directors of Arena Pharmaceuticals and Audentes Therapeutics. Ms. Jarrett received her M.B.A. from Stanford Graduate School of Business and her undergraduate degree in Economics from Dartmouth College.
About Arcus Biosciences
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which will be evaluated in combination with other agents in multiple tumor types in a Phase 1/1b program, and an anti-PD-1 antibody, which is being evaluated in a Phase 1 trial and will be tested in combination with Arcus’s other product candidates. Arcus’s other programs include a small molecule inhibitor of CD73 and an anti-TIGIT antibody, both of which are in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including, but not limited to, the advancement of Arcus’s pipeline, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ significantly from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to, the inherent uncertainty associated with pharmaceutical product development and clinical trials, changes in expected or existing competition and our limited operating history. Risks and uncertainties facing Arcus are described more fully in Arcus’s quarterly report on Form 10-Q for the quarter ended March 31, 2018 filed on May 9, 2018 with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.
Source: Arcus Biosciences